{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:56:26Z","timestamp":1784328986001,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T00:00:00Z","timestamp":1603497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.10.043","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T05:34:48Z","timestamp":1604122488000},"page":"7998-8009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Development of Hillchol\u00ae, a low-cost inactivated single strain Hikojima oral cholera vaccine"],"prefix":"10.1016","volume":"38","author":[{"given":"Tarun","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Kumar Mandyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4238-6004","authenticated-orcid":false,"given":"Stefan L","family":"Nordqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-9474","authenticated-orcid":false,"given":"Michael","family":"Lebens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-2552","authenticated-orcid":false,"given":"Vibhu","family":"Kanchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"L\u00f6fstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Jeverstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mainul Ahasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahbubul","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasneen","family":"Muktadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Muktadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Holmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10101","key":"10.1016\/j.vaccine.2020.10.043_b0005","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0140-6736(17)30559-7","article-title":"Cholera","volume":"390","author":"Clemens","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2020.10.043_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003832","article-title":"Updated global burden of cholera in endemic countries","volume":"9","author":"Ali","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.10.043_b0015","unstructured":"Oral Cholera vaccine market and supply update. UNICEF Supply Division. June 2016."},{"key":"10.1016\/j.vaccine.2020.10.043_b0020","first-page":"231","article-title":"When, how and where can Oral Cholera Vaccines be used to interrupt Cholera Outbreaks?","volume":"379","author":"Clemens","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2020.10.043_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/13f018ff-b71a-4c5e-a276-d4b4ae608fee","article-title":"Cholera vaccination campaign contributes to improved knowledge regarding cholera and improved practice relevant to waterborne disease in rural Haiti","volume":"7","author":"Aibana","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2020.10.043_b0030","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa1312680","article-title":"Use of Vibrio cholerae vaccine in an outbreak in Guinea","volume":"370","author":"Luquero","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.043_b0035","unstructured":"Cholera \u2013 fact sheet N107. World Health Organization 2012."},{"key":"10.1016\/j.vaccine.2020.10.043_b0040","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrgastro.2011.174","article-title":"New\u2013generation vaccines against cholera","volume":"8","author":"Clemens","year":"2011","journal-title":"Nat RevGastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2020.10.043_b0045","unstructured":"WHO Global Taskforce on Cholera Control. Ending Cholera \u2013 A Global Roadmap to 2030. 2017; Oct 3; https:\/\/www.who.int\/cholera\/publications\/global-roadmap\/en\/."},{"issue":"6364","key":"10.1016\/j.vaccine.2020.10.043_b0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.aao2136","article-title":"Integrated view of vibrio cholerae in the Americas","volume":"358","author":"Thomson","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.10.043_b0055","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1073\/pnas.89.7.2566","article-title":"Serotype conversion in Vibrio cholerae O1","volume":"89","author":"Stroeher","year":"1992","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.vaccine.2020.10.043_b0060","article-title":"Development of stable Vibrio cholerae O1 Hikojima type vaccine strains co\u2013expressing the Inaba and Ogawa lipopolysaccharide antigens","volume":"9","author":"Karlsson","year":"2014","journal-title":"PLOS"},{"issue":"13","key":"10.1016\/j.vaccine.2020.10.043_b0065","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0264-410X(92)90324-D","article-title":"An oral B subunit\/whole cell vaccine against cholera","volume":"10","author":"Holmgren","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.043_b0070","first-page":"223","article-title":"A second affordable oral cholera vaccine: implications for the global vaccine stockpile","volume":"4","author":"Desai","year":"2016","journal-title":"Lancet"},{"issue":"45","key":"10.1016\/j.vaccine.2020.10.043_b0075","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.vaccine.2018.09.026","article-title":"The euvichol story \u2013 development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships","volume":"36","author":"Odevall","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.043_b0080","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.vaccine.2019.12.011","article-title":"Current and future cholera vaccines","volume":"38","author":"Shaikh","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.043_b0085","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0140-6736(90)90080-O","article-title":"Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up","author":"Clemens","year":"1990","journal-title":"Lanceti"},{"issue":"8932","key":"10.1016\/j.vaccine.2020.10.043_b0090","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(94)90755-2","article-title":"Protective efficacy of oral whole-cell\/recombinant-B-subunit cholera vaccine in Peruvian military recruits","volume":"344","author":"Sanchez","year":"1994","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2020.10.043_b0095","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMoa043323","article-title":"Effectiveness of mass oral cholera vaccination in Beira","volume":"352","author":"Lucas","year":"2005","journal-title":"Mozambique. N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2020.10.043_b0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1473-3099(12)70196-2","article-title":"Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study","volume":"12","author":"Khatib","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.043_b0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14760584.2017.1291348","article-title":"PaxVax CVD 103-HgR single-dose live oral cholera vaccine","volume":"16","author":"Levine","year":"2017","journal-title":"Expert Review of Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.043_b0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0167-7012(95)00061-5","article-title":"Improved medium for large-scale production of recombinant cholera toxin B subunit for vaccine purposes","volume":"24","author":"Osek","year":"1995","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.vaccine.2020.10.043_b0115","unstructured":"Centers for Disease Control and Prevention. Laboratory methods for the diagnosis of Vibrio cholerae. CDC 1994."},{"key":"10.1016\/j.vaccine.2020.10.043_b0120","first-page":"67","article-title":"Immunogenicity and protective capacity of inactivated \u201cvibrio cholerae\u201d whole cell vaccines","volume":"53","author":"Cryz","year":"1983","journal-title":"Dev Biol Stand."},{"key":"10.1016\/j.vaccine.2020.10.043_b0125","unstructured":"World Health Organization. General requirements for the sterility of Biological substances 1973."},{"key":"10.1016\/j.vaccine.2020.10.043_b0130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0092-1157(80)80019-9","article-title":"Estimation of residual free formaldehyde in biological products","volume":"8","author":"Frerichs","year":"1980","journal-title":"J Biological Standardization"},{"key":"10.1016\/j.vaccine.2020.10.043_b0135","first-page":"169","volume":"22","author":"Knight","year":"1973","journal-title":"Lab Pract"},{"key":"10.1016\/j.vaccine.2020.10.043_b0140","first-page":"83","article-title":"Lipopolysaccharides. Extraction with Phenol-Water and further applications of the Procedure","author":"Westphal","year":"1965","journal-title":"Methods Carbohydr Chem"},{"key":"10.1016\/j.vaccine.2020.10.043_b0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/abio.1998.2961","article-title":"Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation","author":"Lee","year":"1999","journal-title":"Anal Biochem"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.043_b0150","first-page":"72","article-title":"Consensus meeting on international standards for oral whole cell killed cholera vaccines","volume":"1","author":"Odevall","year":"2019","journal-title":"Vaccin Res Open J"},{"key":"10.1016\/j.vaccine.2020.10.043_b0155","doi-asserted-by":"crossref","unstructured":"Borde A1, Larsson A, Holmgren J, Nygren E. Preparation and evaluation of a freeze-dried oral killed cholera vaccine formulation. Eur J Pharm Biopharm 2011;79(3):508-18.","DOI":"10.1016\/j.ejpb.2011.06.009"},{"key":"10.1016\/j.vaccine.2020.10.043_b0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF02601701","article-title":"Identification of Escherichia coli heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure","volume":"1","author":"Svennerholm","year":"1978","journal-title":"Curr Microbio"},{"key":"10.1016\/j.vaccine.2020.10.043_b0165","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1073\/pnas.86.2.481","article-title":"Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development","volume":"86","author":"Sanchez","year":"1989","journal-title":"Proc Natl. Acad Sci"},{"key":"10.1016\/j.vaccine.2020.10.043_b0170","first-page":"257","article-title":"PERFEXT: a direct method for quantitative assessment of cytokine production in vivo at the local level","volume":"148","author":"Villavedra","year":"1997","journal-title":"ResImmunol"},{"key":"10.1016\/j.vaccine.2020.10.043_b0175","unstructured":"Cholera supply and procurement roadmap. GAVI Dec 2018."},{"key":"10.1016\/j.vaccine.2020.10.043_b0180","unstructured":"Repeated dose oral toxicity study of oral cholera vaccine in Sprague-Dawley rats. Nonclinical Research Institute, Chemon Inc. 2016."},{"key":"10.1016\/j.vaccine.2020.10.043_b0185","first-page":"221","article-title":"Experimental studies on cholera immunization. 5. Cross-reactive and type-specific determinants on V. cholera Inaba and Ogawa endotoxin and their significance for protective immunity","volume":"83","author":"Svennerholm","year":"1975","journal-title":"Acta path microbial scand"},{"key":"10.1016\/j.vaccine.2020.10.043_b0190","doi-asserted-by":"crossref","unstructured":"Feeley JC, Gangarosa EJ. Field trials of cholera vaccine. In \u201cCholera and related diarrheas. 43rd Nobel Symp. Stockholm 1978, pp. 204-210 (ed \u00d6 OUchterlony & J Holmgren) Karger, Basel 1980.","DOI":"10.1159\/000403262"},{"issue":"26","key":"10.1016\/j.vaccine.2020.10.043_b0195","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.vaccine.2017.05.005","article-title":"Correlates of protection for enteric vaccines","volume":"35","author":"Holmgren","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.043_b0200","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/IAI.66.2.514-520.1998","article-title":"Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates","volume":"66","author":"Johansson","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.10.043_b0205","unstructured":"Hilleman Lab licenses Oral Cholera Vaccine Hillchol\u00ae to Bharat Biotech. Biospectrum 2019; June26."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:50:04Z","timestamp":1759402204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20313372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":41,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20313372"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Hillchol\u00ae, a low-cost inactivated single strain Hikojima oral cholera vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}